Prevalence, mortality, risk factors, and treatment of carbapenem-resistant hypervirulent Klebsiella pneumoniae: an evidence map
- 1Tianjin First Central Hospital, No. 24 Fukang Road, Nankai District, Tianjin, 300192 China
- 2Value & Implementation, MSD China, Shanghai, 200030 China
Abstract
Purpose: Carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) is a critical global health threat due to its hypervirulence and multidrug resistance, causing severe, high-mortality infections. This study systematically reviews its epidemiology, risk factors, treatment strategies, and activity.
Methods: We searched databases to identify studies reporting CR-hvKP prevalence, resistance profiles, risk factors, treatment strategies, and activity. Two reviewers independently extracted data; a third resolved discrepancies. Results were summarized descriptively.
Results: Forty-three studies involving 9283 carbapenem-resistant K. pneumoniae (CRKP) strains were included. The median prevalence of CR-hvKP among CRKP was 9.40% (IQR 4.40–14.80%) via the string test plus virulence assay. Diabetes (OR = 10.947, P = 0.010) and ICU admission (OR = 16.012, P = 0.003) were independent risk factors for CR-hvKP infection. Among 130 patients, the most commonly used antibiotics included meropenem (34.62%), cefoperazone-sulbactam (31.54%), and tigecycline (28.46%). However, treatment failure remains a significant concern. Antimicrobial resistance analysis indicated that CR-hvKP exhibited high resistance rates to cephalosporins (> 80%) and quinolones (45–100%). One study found high susceptibility (92.50–100.00%) to nitrofurantoin, polymyxins, imipenem-relebactam, tigecycline, and colistin. Mortality analysis revealed a median mortality rate of 30.30% (IQR 13.33–53.06%).
Conclusion: CR-hvKP remains a formidable public health threat due to its substantial prevalence, elevated mortality, and multidrug resistance. Current therapeutic strategies lack standardization, and widely applied combination therapy has inconsistent efficacy. Further research is urgently needed to optimize treatment regimens. Early detection, precise antimicrobial stewardship, and stringent infection control measures are crucial to mitigate the spread and impact of CR-hvKP.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s15010-026-02849-0.
Related
- L-histidine metabolic reprogramming is associated with imipenem-relebactam resistance in carbapenem-resistant hypervirulent Klebsiella pneumoniae
- Beyond Resistance: Carbapenemase Gene Profiles and Mortality in ICU Patients with Carbapenem-Resistant Klebsiella pneumoniae Infections
- Hypervirulent Klebsiella pneumoniae Infections in Vancouver, Canada: A Clinical, Microbiological, and Genetic Retrospective Investigation
- Five-Biomarker Definition for Hypervirulent Klebsiella pneumoniae Bloodstream Infection and Abscess Complications, Japan, 2022–2024
- Phytochemical screening as an inhibitor of β-lactamases to overcome the carbapenem-resistant of Klebsiella pneumoniae
BibTeX
@article{chai2026prevalence,
title = {{Prevalence, mortality, risk factors, and treatment of carbapenem-resistant hypervirulent Klebsiella pneumoniae: an evidence map}},
author = {Xiaoyu Chai and Qianyi Zhou and Wei Jiang and Jie Liu and Yue Liu and Yi Sun and Wenjie Yang},
journal = {Infection},
year = {2026},
month = aug,
doi = {10.1007/s15010-026-02849-0},
url = {https://doi.org/10.1007/s15010-026-02849-0},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Prevalence, mortality, risk factors, and treatment of carbapenem-resistant hypervirulent Klebsiella pneumoniae: an evidence map
AU - Xiaoyu Chai
AU - Qianyi Zhou
AU - Wei Jiang
AU - Jie Liu
AU - Yue Liu
AU - Yi Sun
AU - Wenjie Yang
PY - 2026
DA - 2026/08/19
JO - Infection
DO - 10.1007/s15010-026-02849-0
UR - https://doi.org/10.1007/s15010-026-02849-0
AB - Purpose: Carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) is a critical global health threat due to its hypervirulence and multidrug resistance, causing severe, high-mortality infections. This study systematically reviews its epidemiology, risk factors, treatment strategies, and activity. Methods: We searched databases to identify studies reporting CR-hvKP prevalence, resistance profiles, risk factors, treatment strategies, and activity. Two reviewers independently extracted data; a third resolved discrepancies. Results were summarized descriptively. Results: Forty-three studies involving 9283 carbapenem-resistant K. pneumoniae (CRKP) strains were included. The median prevalence of CR-hvKP among CRKP was 9.40% (IQR 4.40–14.80%) via the string test plus virulence assay. Diabetes (OR = 10.947, P = 0.010) and ICU admission (OR = 16.012, P = 0.003) were independent risk factors for CR-hvKP infection. Among 130 patients, the most commonly used antibiotics included meropenem (34.62%), cefoperazone-sulbactam (31.54%), and tigecycline (28.46%). However, treatment failure remains a significant concern. Antimicrobial resistance analysis indicated that CR-hvKP exhibited high resistance rates to cephalosporins (> 80%) and quinolones (45–100%). One study found high susceptibility (92.50–100.00%) to nitrofurantoin, polymyxins, imipenem-relebactam, tigecycline, and colistin. Mortality analysis revealed a median mortality rate of 30.30% (IQR 13.33–53.06%). Conclusion: CR-hvKP remains a formidable public health threat due to its substantial prevalence, elevated mortality, and multidrug resistance. Current therapeutic strategies lack standardization, and widely applied combination therapy has inconsistent efficacy. Further research is urgently needed to optimize treatment regimens. Early detection, precise antimicrobial stewardship, and stringent infection control measures are crucial to mitigate the spread and impact of CR-hvKP. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s15010-026-02849-0.
SN - 0300-8126
SN - 1439-0973
ER -